Published in Nat Rev Gastroenterol Hepatol on October 12, 2010
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver Int (2014) 1.38
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int (2013) 0.87
Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol (2012) 0.87
Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol (2014) 0.85
Liver Transplantation for Patients with Cholestatic Liver Diseases. Viszeralmedizin (2015) 0.83
S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One (2012) 0.81
Cholangiocarcinoma with respect to IgG4 Reaction. Int J Hepatol (2014) 0.79
Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol (2014) 0.76
Immunoglobulin G4-mediated sclerosing cholangitis as a risk factor for cholangiocarcinoma: A case report. Mol Clin Oncol (2016) 0.75
Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol (2017) 0.75
Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. PLoS One (2016) 0.75
Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis. World J Gastroenterol (2013) 0.75
Gene-Targeted Next-Generation Sequencing Identifies a Novel CLDN1 Mutation in a Consanguineous Family With NISCH Syndrome. Am J Gastroenterol (2017) 0.75
Primary biliary cirrhosis. Hepatology (2009) 5.35
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 2.44
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med (1997) 2.41
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology (2000) 2.21
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol (2002) 1.96
Primary sclerosing cholangitis. N Engl J Med (1995) 1.94
The natural history of small-duct primary sclerosing cholangitis. Gastroenterology (2008) 1.92
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
The liver in celiac disease. Hepatology (2007) 1.81
Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology (1991) 1.73
A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl (2009) 1.72
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol (2006) 1.71
Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol (2008) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol (2000) 1.67
Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol (2002) 1.67
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc (2001) 1.66
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65
High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol (2008) 1.64
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology (2001) 1.60
Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol (1998) 1.57
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
The combined measurement of total serum IgG and IgG4 may increase diagnostic sensitivity for autoimmune pancreatitis without sacrificing specificity, compared with IgG4 alone. Am J Gastroenterol (2009) 1.50
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology (2005) 1.45
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology (2007) 1.45
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med (2004) 1.43
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology (1986) 1.43
Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38
Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol (1980) 1.28
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology (1999) 1.26
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol (2004) 1.20
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol (1999) 1.18
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc (2002) 1.16
Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology (1999) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology (1989) 1.13
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol (2001) 1.12
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology (2010) 1.09
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy (2002) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum (2001) 1.06
Transplantation for hilar cholangiocarcinoma. Liver Transpl (2004) 1.05
Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut (2002) 1.05
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol (2005) 1.01
Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology (2004) 1.01
Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1983) 1.00
Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol (2000) 0.99
Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol (1998) 0.98
The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology (1997) 0.97
Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl (2003) 0.97
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol (2002) 0.96
Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study. Radiology (2000) 0.95
The metabolic bone disease of primary sclerosing cholangitis. Hepatology (1991) 0.95
Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation (2004) 0.93
Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology (2001) 0.93
Immune-mediated liver injury. Semin Liver Dis (2007) 0.93
Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol (1995) 0.88
Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol (2006) 0.88
The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience. Can J Gastroenterol (2010) 0.87
Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol (2001) 0.86
Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg (1998) 0.85
Mortality attributable to cholestatic liver disease in the United States. Hepatology (2008) 0.85
A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol (2008) 0.83
Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int (2005) 0.82
Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology (2002) 0.82
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol (2005) 1.05
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol (2011) 1.02
Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis (2006) 1.02
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol (2003) 1.00
Evaluating sex and gender competencies in the medical curriculum: a case study. Gend Med (2012) 1.00
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 0.99
Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol (2009) 0.99
Living donor liver transplantation using a right lobe graft in an adult with situs inversus. Liver Transpl (2005) 0.97
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol (2013) 0.97
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol (2002) 0.96
Putting the needs of the patient first: Mayo Clinic's core value, institutional culture, and professionalism covenant. Acad Med (2007) 0.95
Drug-induced cholestasis. Clin Liver Dis (2003) 0.94
Primary sclerosing cholangitis. Inflamm Bowel Dis (2005) 0.94
Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol (2011) 0.93
Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci (2008) 0.93
Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep (2006) 0.93
Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol (2004) 0.93
Primary sclerosing cholangitis. Clin Liver Dis (2004) 0.92
Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol (2014) 0.92
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol (2013) 0.91
American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology (2010) 0.91
A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Dig Liver Dis (2010) 0.90
Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol (2011) 0.89
Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep (2010) 0.89
Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology (2008) 0.88
Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther (2011) 0.88
Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opin Pharmacother (2010) 0.87
Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol (2012) 0.87
Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2010) 0.87
Current pharmacotherapy for cholestatic liver disease. Expert Opin Pharmacother (2012) 0.87
Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis (2012) 0.87
A model for integration of formal knowledge and clinical experience: the advanced doctoring course at Mayo Medical School. Acad Med (2011) 0.86
Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol Clin North Am (2008) 0.86
Autoimmune hepatitis: a review. J Gastroenterol (2012) 0.86
Value of determining carbohydrate-deficient transferrin isoforms in the diagnosis of alcoholic liver disease. Mayo Clin Proc (2003) 0.86
Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis (2013) 0.85
Current management of primary sclerosing cholangitis in pediatric patients. Paediatr Drugs (2011) 0.85
Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis. Gastroenterol Hepatol (N Y) (2010) 0.85
Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol (2009) 0.85
Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol (2012) 0.85
Commentary: improving medical education during financially challenging times. Acad Med (2010) 0.85
Mortality attributable to cholestatic liver disease in the United States. Hepatology (2008) 0.85